All In Biotech

Drug Trial Radar · NCT00094770

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)

A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy

Last checked: Nov 20, 2026Latest source record: Aug 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,172 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,172

Actual

Start

Sep 2004

Primary completion

May 2006

Study completion May 2007

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 25, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 78 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this investigational study is to determine the safety and effectiveness of an investigational drug in patients with type 2 diabetes mellitus (a specific type of diabetes).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • sitagliptin (MK0431)Drug

    Sitagliptin 100 mg oral tablets of sitagliptin once daily.

  • Comparator: glipizideDrug

    Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in HbA1c at Week 52Time frame: Baseline and Week 52

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.